The groundbreaking success of Sildenafil undeniably revolutionized the drug landscape, but investing in companies primarily reliant on off-patent versions presents a complex picture. Although early returns were substantial, the end of patents and the appearance of less expensive alternatives have weakened the customer base. Therefore, a thorough as